NASH Populations with Cirrhosis: Drug Development Challenges

Toronto, ON (PRWEB) January 24, 2022 -- Nonalcoholic fatty liver disease (NAFLD) has become the most common cause of chronic liver disease worldwide.

Related Keywords

United Kingdom , Johnm Vierling , Claudia Filozof , Lara Dimick Santos , Labcorp Drug Development , Honeycomb Worldwide Inc , Baylor Liver Health , Baylor College Of Medicine , Drug Development , Baylor College , Drug Development Challenges , Life Science , Press Release ,